在接受瓦尔酸治疗的患者中,高氨血症的危险因素和多重相互作用效应
Chien-Chou Su1, Tsai-Kuei Huang2, Ching-Sen Shih3
1Clinical Innovation and Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Fundamental & clinical pharmacology
|June 22, 2025
概括
瓦尔酸 (VPA) 的使用增加了高氨血症 (HA) 的风险. 年轻的患者,患者或多药患者面临更高的风险,特别是在VPA水平升高的情况下.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床毒理学 临床毒理学
- 数据科学数据科学数据科学
背景情况:
- 瓦尔酸 (VPA) 与高氨血症 (HA) 风险有关.
- 在接受VPA治疗的患者中,HA风险因素的相互作用尚未完全理解.
研究的目的:
- 在接受VPA治疗的患者中识别和评估HA风险因素的相互作用.
- 改善VPA治疗的临床风险分层.
主要方法:
- 回顾性队列研究 (2019-2021年).
- 沙普利添加式解释 (SHAP) 用于模型解释和相互作用分析.
- 对影响HA的风险因素相互作用的分析.
主要成果:
- 确定了前15个HA预测因素:年龄,VPA度,VPA剂量,,VPA持续时间, levetiracetam,高血压,精神障碍,药物数量.
- 显著的相互作用:年龄与VPA度,和治疗持续时间.
- 年轻的患者,升高的VPA,,或多药性增加HA的风险.
结论:
- 确定了影响VA患者HA的关键因素,特别是在年轻人,患者或多药患者中.
- 由于回顾性,单中心设计,研究结果需要进一步验证.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
461
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
461
Antiepileptic Drugs: Glutamate Antagonists
527
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
527
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
312
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
312
Factors Affecting Protein-Drug Binding: Drug Interactions
291
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
291
Hepatic Drug Excretion: Influencing Factors
242
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
242
Factors Affecting Protein-Drug Binding: Patient-Related Factors
123
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
123


